We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+41.65%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.17B
AUM Growth
+$2.33B
Cap. Flow
+$258M
Cap. Flow %
4.18%
Top 10 Hldgs %
45.67%
Holding
151
New
35
Increased
25
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$54.2M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$47.1M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$40.3M
4
ZGNX
Zogenix, Inc.
ZGNX
+$40.1M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$38.9M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$102M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$53.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.9M
4
TBPH icon
Theravance Biopharma
TBPH
+$23.1M
5
NVRO
NEVRO CORP.
NVRO
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.05%
2 Financials 0.28%
3 Materials 0.1%
4 Technology 0.1%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCAT icon
76
Health Catalyst
HCAT
$157M
$9.79M 0.16%
335,782
+7,084
+2% +$196K
CHRS icon
77
Coherus Oncology
CHRS
$217M
$9.74M 0.16%
+545,285
New +$9.23M
REGN icon
78
Regeneron Pharmaceuticals
REGN
$73B
$9.35M 0.15%
15,000
-65,000
-81% -$36.9M
NGNE icon
79
Neurogene
NGNE
$648M
$8.92M 0.14%
26,871
+1,871
+7% +$488K
AQST icon
80
Aquestive Therapeutics
AQST
$467M
$8.51M 0.14%
+1,750,000
New +$8.06M
ONEM
81
DELISTED
1Life Healthcare
ONEM
$7.95M 0.13%
218,844
+33,844
+18% +$953K
LGVW.U
82
DELISTED
Longview Acquisition Corp. Units, each consisting of one share of Class A common stock, and one-thir
LGVW.U
$7.07M 0.11%
+700,000
New +$7.02M
BIO icon
83
Bio-Rad Laboratories Class A
BIO
$8.8B
$6.99M 0.11%
15,489
+12,000
+344% +$5.3M
AMRS
84
DELISTED
Amyris Inc.
AMRS
$6.45M 0.1%
+1,844,612
New +$6.13M
DMTK
85
DELISTED
DermTech, Inc. Common Stock
DMTK
$6.45M 0.1%
487,121
+201,265
+70% +$2.62M
MRNA icon
86
PUT
Moderna
MRNA
$21.7B
$6.42M 0.1%
+100,000
New +$5.48M
VCRA
87
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$6.15M 0.1%
290,000
-180,000
-38% -$3.53M
TBIO
88
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$5.65M 0.09%
315,237
-119,763
-28% -$1.81M
MOTS
89
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$5.56M 0.09%
14,035
– –
VERU icon
90
Veru
VERU
$35.2M
$5.51M 0.09%
165,000
– –
VRAY
91
DELISTED
ViewRay, Inc.
VRAY
$5.49M 0.09%
2,451,748
– –
AXSM icon
92
Axsome Therapeutics
AXSM
$11.7B
$4.11M 0.07%
+50,000
New +$3.85M
BNR
93
Burning Rock Biotech
BNR
$94M
$4.05M 0.07%
+15,000
New +$4.11M
ADAP
94
DELISTED
Adaptimmune Therapeutics
ADAP
$4M 0.06%
+400,000
New +$2.51M
IMMU
95
PUT
DELISTED
Immunomedics Inc
IMMU
$3.54M 0.06%
+100,000
New +$2.92M
LSACU
96
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$3.3M 0.05%
300,000
– –
ATEC icon
97
Alphatec Holdings
ATEC
$1.45B
$2.64M 0.04%
561,574
– –
GRTX
98
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.32M 0.04%
325,000
– –
PHR icon
99
Phreesia
PHR
$692M
$1.98M 0.03%
70,000
– –
MDT icon
100
Medtronic
MDT
$113B
$1.83M 0.03%
+20,000
New +$1.92M
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Perceptive Advisors held 151 positions worth $6.17B, up 61% from $3.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors deployed $258M of net new capital in Q2 2020, opening 35 new positions and adding to 25 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 95% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $102M trimmed.

  • Perceptive Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.
  • Perceptive Advisors added most to Zogenix, Inc. in Q2 2020, an estimated $40.1M increase.
  • Perceptive Advisors's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $102M.
  • Perceptive Advisors fully exited Theravance Biopharma in Q2 2020, selling an estimated $23.1M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $6.17B portfolio in Q2 2020.
  • Perceptive Advisors opened 35 new positions and closed 26 in Q2 2020.
  • Perceptive Advisors's portfolio value rose 61% quarter-over-quarter to $6.17B.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.